Edison, New Jersey headquartered ContraVir Pharmaceuticals Inc.'s stock finished last Friday's session 1.32% lower at $1.50. A total volume of 223,457 shares was traded. The Company's shares have advanced 10.29% in the previous three months and 25.00% since the start of this year. The stock is trading above its 200-day moving average by 15.78%. Additionally, shares of ContraVir Pharmaceuticals, which operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus infections, have a Relative Strength Index (RSI) of 46.08.
On January 03rd, 2017, ContraVir Pharma announced that it was awarded a $297,875 CAD research grant from the National Research Council in Canada through the Council's Industrial Research Assistance Program. Proceeds from the grant will fund a substantial portion of personnel expenses, including the hiring of additional laboratory staff, which is expected to advance preclinical development of ContraVir's potent cyclophilin inhibitor CRV431 for the Treatment of Hepatitis B. See our free and comprehensive research report on CTRV at:
On Friday, shares in San Diego, California-based Arena Pharmaceuticals Inc. ended the session 2.07% lower at $1.42. The stock recorded a trading volume of 1.96 million shares, which was higher than its three months average volume of 1.57 million shares. The Company's shares are trading 4.49% below their 50-day moving average. Moreover, shares of Arena Pharma, which discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the US and South Korea, have an RSI of 42.77.
On January 05th, 2017, Eisai Co., Ltd announced that, in association with its US pharmaceutical subsidiary Eisai Inc., it has reached an agreement with Arena Pharma to revise the November 2013 marketing and supply agreement it concluded with Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, for the chronic weight management treatment lorcaserin hydrochloride (generic name, US brand name: BELVIQ / BELVIQ XR). Under the new agreement, Eisai acquires all of Arena's rights to develop and market BELVIQ. The previously negotiated financial terms such as purchase price based on net sales and regulatory and sales milestones to Arena have also been reduced and modified. ARNA free research report PDF is just a click away at:
Germantown, Maryland headquartered Neuralstem Inc.'s shares dropped 3.21%, closing the session at $4.22 with a total trading volume of 259,997 shares. The stock has surged 1407.14% in the last one month, 1261.29% over the previous three months, and 539.39% on an YTD basis. The Company's shares are trading 568.36% above their 50-day moving average. Additionally, shares of Neuralstem, which focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds, have an RSI of 72.70.
On January 06th, 2017, Neuralstem announced a reverse stock split of its shares of common stock at a ratio of 1-for-13. The reverse stock split will become effective on January 06th, 2017 after market close. The reverse stock split enables Neuralstem to regain compliance with the $1.00 minimum bid price condition and thereby fulfill all of the NASDAQ Capital Market continued listing requirements. Sign up for your complimentary report on CUR at:
Last Friday at the close, Seattle, Washington headquartered CTI BioPharma Corp.'s stock recorded a trading volume of 340,521 shares, and ended the session 4.44% higher at $5.64. The Company's shares have skyrocketed 1,047.74% in the past month, 1,386.56% over the previous three months, and 1,283.71% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 390.95% and 848.78%, respectively. Furthermore, shares of CTI BioPharma, which engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the US and internationally, have an RSI of 87.23.
On January 05th, 2017, CTI BioPharma announced that the full clinical hold (February 2016) implemented by the US FDA on all clinical trials conducted under the Investigational New Drug application for pacritinib has now been removed. The Company expects to start the trial in Q2 2017. Register for free on Stock-Callers.com and download the latest research report on CTIC at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA